Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to Strong-Buy at Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Other equities research analysts also recently issued reports about the company. Evercore ISI upped their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research report on Thursday, September 11th. Needham & Company LLC raised their price target on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Finally, Royal Bank Of Canada lifted their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, September 19th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $466.92.

Alnylam Pharmaceuticals Trading Down 0.1%

NASDAQ:ALNY opened at $463.43 on Friday. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The business has a fifty day moving average price of $459.27 and a 200-day moving average price of $360.03. The firm has a market capitalization of $60.75 billion, a price-to-earnings ratio of -187.62 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business’s revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 over the last quarter. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. ORG Partners LLC lifted its holdings in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 33 shares during the period. Hilltop National Bank purchased a new stake in Alnylam Pharmaceuticals during the third quarter worth $41,000. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $30,000. Finally, SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.